{"id":890136,"date":"2025-09-29T09:06:37","date_gmt":"2025-09-29T13:06:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/"},"modified":"2025-09-29T09:06:37","modified_gmt":"2025-09-29T13:06:37","slug":"signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/","title":{"rendered":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows<\/b><\/p>\n<p class=\"bwalignc\"><i>Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=7b41169154ff19c7fd4701b33ce5922a\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fascopubs.org%2Fdoi%2Fpdf%2F10.1200%2FPO-25-00286&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Oncology+Precision+Oncology&amp;index=2&amp;md5=272afe1b199eefb33c008ee281b1374f\"><i>Journal of Clinical Oncology Precision Oncology<\/i><\/a><i> (JCO PO),<\/i> validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer.<\/p>\n<p>\nUterine cancer is the most common gynecologic malignancy in the United States.<sup>1<\/sup> While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.<sup>2<\/sup> For patients with early-stage, high or higher-intermediate risk uterine cancer, there are limited tools to individualize recurrence risk and direct therapy.<\/p>\n<p>\nThis recently published, real-world, multi-center, retrospective study analyzed 233 plasma samples from 61 patients with stage I\/II uterine cancer who had undergone surgical staging.<\/p>\n<p>\nKey findings from the study include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSignatera positivity was highly prognostic of recurrence in both the postoperative (HR=7.6; p=0.003) and post-definitive therapy (HR=25.4, p=0.0009) settings.<\/p>\n<\/li>\n<li>\nSignatera status was the most prognostic risk factor, outperforming conventional clinicopathologic factors.<\/p>\n<\/li>\n<li>\nAmong patients with Signatera surveillance testing, 100% tested positive before clinically confirmed recurrence, with a median lead time of 3.1 months. None of the serially Signatera-negative patients experienced recurrence.<\/p>\n<\/li>\n<\/ul>\n<p>\nAdditionally, the study further supports the conclusions of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38262240%2F&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=Recio+et+al.+2024&amp;index=3&amp;md5=ef0be1f361f88696122bbec790785956\">Recio et al. 2024<\/a><sup>3<\/sup>, which established postoperative and longitudinal Signatera testing as a highly prognostic tool in early-stage uterine cancer.<\/p>\n<p>\n\u201cIn our study, ctDNA positivity was more prognostic of recurrence than any of the traditional risk stratification factors used in practice, and importantly, it is individualized for every patient,\u201d said Michael Toboni, M.D., MPH, gynecologic oncologist at the University of Alabama at Birmingham and principal investigator of the study. \u201cThese findings support the potential utility of ctDNA testing as a way to de-escalate and ultimately reduce unnecessary and toxic treatment in early-stage patients.\u201d<\/p>\n<p>\n\u201cSignatera consistently identified early-stage uterine cancer patients at high risk of recurrence, and predicted recurrences prior to clinical diagnoses,\u201d said Adam ElNaggar, M.D., senior medical director of oncology at Natera. \u201cThese insights can inform surveillance strategies and give patients and their care teams more confidence following surgery.\u201d<\/p>\n<p><b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nCDC, <i>et al.<\/i> Uterine Cancer Statistics. <i>Centers for Disease Control and Prevention.<\/i> Accessed September 24, 2025. URL: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cdc.gov%2Futerine-cancer%2Fstatistics%2F%3Futm_source%3Dchatgpt.com&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cdc.gov%2Futerine-cancer%2Fstatistics%2F&amp;index=4&amp;md5=0793f538c9ecbbf3de561310feb591f5\">https:\/\/www.cdc.gov\/uterine-cancer\/statistics\/<\/a><\/li>\n<li>\nGordhandas, Sushmita et al. \u201cCurrent Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.\u201d <i>Journal of the National Comprehensive Cancer Network : JNCCN<\/i> vol. 21,2 (2023): 217-226. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjnccn.org%2Fview%2Fjournals%2Fjnccn%2F21%2F2%2Farticle-p217.xml&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=doi%3A10.6004%2Fjnccn.2022.7254&amp;index=5&amp;md5=dc0839e180d71d155d51e751bc9ff786\">doi:10.6004\/jnccn.2022.7254<\/a><\/li>\n<li>\nRecio, F., et al. \u201cPost-Surgical ctDNA-Based Molecular Residual Disease Detection in Patients with Stage I Uterine Malignancies.\u201d <i>Gynecologic Oncology<\/i>, vol. 182, 2024, pp. 63\u201369. Elsevier, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.ygyno.2023.12.025&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.ygyno.2023.12.025&amp;index=6&amp;md5=c156beb586c4b8db6204b0c446bb5b35\">https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.025<\/a><\/li>\n<\/ol>\n<p><b>About Natera<\/b><\/p>\n<p>\nNatera\u2122 is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=7&amp;md5=37aaed820357a6267ac81c8ad8c87dc8\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in &#8220;Risk Factors&#8221; in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=8&amp;md5=9052ae0221b97815c194dfe336405cce\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54330639&amp;newsitemid=20250929370894&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=46fc181027d5b2372ca019e8cbc459a8\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250929370894\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250929370894\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<\/a><\/p>\n<p>\nMedia: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Women Genetics Clinical Trials Health Technology Biotechnology Health Consumer General Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250929370894\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the most common gynecologic malignancy in the United States.1 While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.2 For patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890136","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the most common gynecologic malignancy in the United States.1 While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.2 For patients with &hellip; Continue reading &quot;Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T13:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows\",\"datePublished\":\"2025-09-29T13:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/\"},\"wordCount\":794,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/\",\"name\":\"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-09-29T13:06:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/","og_locale":"en_US","og_type":"article","og_title":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk","og_description":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the most common gynecologic malignancy in the United States.1 While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.2 For patients with &hellip; Continue reading \"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T13:06:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows","datePublished":"2025-09-29T13:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/"},"wordCount":794,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/","name":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-09-29T13:06:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250929370894r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/signatera-surveillance-testing-identified-100-of-uterine-cancer-recurrences-in-advance-of-imaging-new-study-shows\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Signatera\u2122 Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890136"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890136\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}